Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IDSA/PIDS announce guidelines for treating pneumonia in children

31.08.2011
Immunization, including flu vaccine, can thwart pneumonia in children, guidelines suggest

Immunizations, including a yearly flu vaccine, are the best way to protect children from life-threatening pneumonia, according to new guidelines from the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA).

The guidelines, which are the first on diagnosing and treating community-acquired pneumonia (CAP) in infants and children, place preventing bacterial pneumonia as a top priority.

Every year, pneumonia kills more than 2 million children ages 5 years and younger worldwide. In the United States, 525 children 15 years old or younger died from pneumonia and other lower respiratory infections in 2006, according to the Centers for Disease Control and Prevention (CDC). While pneumonia can be caused by different types of bugs, in infants and preschool children it usually is caused by a virus, which doesn't need to be treated with antibiotics. However, antibiotics are needed for bacterial pneumonia, which is the most serious type.

Although there are guidelines for diagnosing and treating pneumonia in adults, the course of bacterial pneumonia tends to be different for children. Because of this, practices vary from hospital to hospital, and doctor to doctor. The guidelines from PIDS and IDSA provide all physicians who care for children with a roadmap to the most scientifically valid diagnosis and treatment recommendations.

"Diagnostic methods and treatments that work well in adults may be too risky and not have the desired result in children," said John S. Bradley, MD, lead author of the CAP guidelines and professor and chief of the division of infectious diseases at the University of California at San Diego Department of Pediatrics. "With these guidelines, we are hopeful that the standard and quality of care children receive for community-acquired pneumonia will be consistent from doctor to doctor – providing much better treatment outcomes."

Because viral infections such as influenza can develop into bacterial pneumonia, it's important that children 6 months and older receive a yearly influenza vaccine, according to the guidelines. It is also important that infants and children are up to date on their other scheduled vaccines, several of which prevent bacterial pneumonia. The successful U.S. vaccination program has significantly reduced bacterial pneumonia, and therefore has prevented deaths from the infection, notes Dr. Bradley.

While the guidelines stress the importance of diagnosing pneumonia appropriately, they also warn that over-treatment is a critical concern. For instance, most pneumonia in preschool-aged children is viral, meaning it will run its course and will not develop into life-threatening bacterial pneumonia. In these cases, there is no need to perform unnecessary medical interventions such as using x-rays (which expose the child to radiation needlessly) or prescribing antibiotics (which kill bacteria, not viruses, and may foster drug-resistant bacteria).

"A child with chest congestion, a cough, runny nose and low-grade fever likely has viral pneumonia, and Mother Nature treats those herself," said Dr. Bradley. "If the child has a fever of 104, is barely able to keep fluids down, just wants to lie in bed and is breathing fast, it may be bacterial pneumonia and require antibiotics and hospitalization."

The guidelines suggest when doctors can feel comfortable not prescribing a higher level of care and when they need to be cautious, and do so. By design, the guidelines lead off with recommendations regarding hospitalization. "Most of these kids will have their first encounter when they have fever and difficulty breathing and see their primary care physician, or the emergency room doctor," said Dr. Bradley. "The first major decision that needs to be made is, is this child well enough to go home, or does he or she need a higher level of care?"

For instance, the guidelines recommend infants 3 to 6 months old with suspected bacterial pneumonia are likely to benefit from hospitalization, even if the pneumonia isn't confirmed by blood tests. Blood testing in children often isn't accurate, so physicians need to pay close attention to symptoms, and, if unsure, err on the side of treating, said Dr. Bradley.

Following are some other recommendations included in the guidelines:

Because infants 6 months and younger cannot get the flu shot or nasal spray, their parents and caregivers should be sure to get the vaccine.
When antibiotics are necessary, amoxicillin should be first-line therapy for bacterial pneumonia, because it is safe and effective. Many doctors prescribe more powerful antibiotics, which are unnecessary and can kill off good bacteria in the body.

Although pneumonia from methicillin-resistant Staphylococcus aureus (MRSA) is uncommon, it can cause severe illness, so physicians need to consider it if a child doesn't improve after first-line antibiotic therapy.

For each of the 92 specific recommendations, the guidelines denote the strength of the recommendation as well as the quality of evidence for each. The guidelines note the lack of solid evidence in some areas – often due to the ethical challenges of studying children – and call for research in specific areas.

"We're hopeful that in following these guidelines, physicians and hospitals will collect data and the results can be compared," said Dr. Bradley. "We envision this as the first of many revisions of guidelines to come."

The 13-member guidelines panel was comprised of experts from around the country, including lung, emergency department, hospital medicine and critical care specialists, office-based pediatricians, pediatric surgeons and CDC epidemiologists. They reviewed hundreds of scientific studies, papers and presentations in preparation for writing the guidelines. In addition to Dr. Bradley, the panel included: Carrie L. Byington, Samir S. Shah, Brian Alverson, Edward R. Carter, Christopher Harrison, Sheldon L. Kaplan, Sharon E. Mace, George H. McCracken, Jr., Matthew R. Moore, Shawn D. St. Peter, Jana A. Stockwell and Jack T. Swanson.

IDSA has published more than 50 treatment guidelines on various conditions and infections, ranging from HIV/AIDS to Clostridium difficile. As with other IDSA guidelines, the CAP in children guidelines will be available in a format designed for iPhones and other mobile devices, and in a pocket-sized quick-reference edition. These are the first guidelines published by PIDS.

Note: For a copy of The Management of Community-Acquired Pneumonia (CAP) in Infants and Children Older than 3 months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA), to be published in the October 1 issue of Clinical Infectious Diseases, please contact Ashley Mattys at (312) 558-1770 or amattys@pcipr.com. The guidelines are embargoed until Aug. 31, 2011 at 12:01 a.m. ET, when they will be posted online.

The Pediatric Infectious Diseases Society (PIDS) is an organization of more than 1,000 specialists in pediatric infectious diseases, covering areas from basic and clinical research to patient care. PIDS' mission is to enhance the health of infants, children and adolescents by promoting excellence in diagnosis, management and prevention of infectious diseases through clinical care, education, research and advocacy. PIDS represents the leading practitioners, policy-makers and researchers who work with children's infectious diseases. For more information, visit www.pids.org.

The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, patient care, prevention, and public health. The Society, which has more than 9,000 members, was founded in 1963 and is based in Arlington, Va. For more information, visit www.idsociety.org.

Ashley Mattys | EurekAlert!
Further information:
http://www.idsociety.org

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>